Although further studies are needed to determine the precise cleavage sites on AXL and the mechanism in which YD enhances the action of PS-RIP, the findings suggest that the modulation of AXL turnover may be a promising therapeutic target for EGFR-TKI-resistant NSCLC cells. This evidence concerns the gene EGFR and non-small cell lung carcinoma.